Xenon's XEN1101 Meets its Primary Efficacy Endpoint in P-IIb X-TOLE Clinical Trial for the Treatment of Focal Epilepsy
Shots:
- The P-IIb X-TOLE clinical trial evaluates the efficacy- safety- & tolerability of XEN1101 (25/20/10mg) vs PBO in 325 & 323 patients (in the safety & ITT population- respectively) with focal epilepsy
- The trial met its 1EPs i.e.- patients achieved a median reduction in monthly focal seizure frequency from baseline (52.8%/46.4%/33.2% vs 18.2%)- and other measures included a ≥50% reduction in monthly focal seizure frequency from baseline (54.5%/43.1/28.3 vs 14.9). The therapy was generally well-tolerated
- The therapy leads to treatment discontinuation due to AEs (15.8%/13.7%/ 2.2% vs 3.5)- higher incidence of TEAEs (85.1%/ 68.6%/ 67.4% vs 62.3)
| Ref: Globe Newswire | Image: BioSpace
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com